IGC Pharma (IGC) Assets Average (2011 - 2026)
IGC Pharma (IGC) posted quarterly Assets Average of $9.4 million for Q1 2026, up 6.01% year-over-year from $8.9 million in Q1 2025, and down 2.87% quarter-over-quarter from $9.7 million in Q4 2025.
IGC Pharma (IGC) Assets Average (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Assets Average for 16 consecutive years, with $9.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 6.01% year-over-year to $9.4 million; the TTM figure through Mar 2026 stood at $9.4 million (up 6.01% YoY), while the FY2026 annual figure was $9.0 million, down 3.84% from the prior year.
- Assets Average retreated to $9.4 million in Q1 2026 per IGC's latest filing, from $9.7 million in the prior quarter.
- Across five years, Assets Average topped out at $29.1 million in Q1 2022 and bottomed at $8.3 million in Q2 2025.
- Historically, Assets Average has averaged $14.7 million across 5 years, with a median of $10.6 million in 2024.
- Annual changes were most pronounced in 2024 — Assets Average slumped 43.19% — and 2026, when it gained 6.01%.
- IGC Pharma's Assets Average stood at $21.0 million in 2022, then tumbled by 33.94% to $13.9 million in 2023, then fell by 29.96% to $9.7 million in 2024, then advanced by 0.04% to $9.7 million in 2025, then declined by 2.87% to $9.4 million in 2026.
- Business Quant data shows IGC's Assets Average at $9.4 million in Q1 2026, $9.7 million in Q4 2025, and $8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | 9.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.45 Mn |
| Dec 31, 2025 | 9.73 Mn |
| Sep 30, 2025 | 8.84 Mn |
| Jun 30, 2025 | 8.35 Mn |
| Mar 31, 2025 | 8.91 Mn |
| Dec 31, 2024 | 9.72 Mn |
| Sep 30, 2024 | 10.48 Mn |
| Jun 30, 2024 | 10.25 Mn |
| Mar 31, 2024 | 10.58 Mn |
| Dec 31, 2023 | 13.88 Mn |
| Sep 30, 2023 | 16.09 Mn |
| Jun 30, 2023 | 16.43 Mn |
| Mar 31, 2023 | 18.62 Mn |
| Dec 31, 2022 | 21.01 Mn |
| Sep 30, 2022 | 23.06 Mn |
| Jun 30, 2022 | 25.50 Mn |
| Mar 31, 2022 | 29.06 Mn |
| Dec 31, 2021 | 32.56 Mn |
| Sep 30, 2021 | 34.14 Mn |
| Jun 30, 2021 | 35.16 Mn |